Supernus Pharmaceuticals (SUPN) Capital Expenditures (2011 - 2025)
Supernus Pharmaceuticals (SUPN) reported Capital Expenditures of $427000.0 for Q4 2025, up 100.47% year-over-year from $213000.0 in Q4 2024, and up 231.01% quarter-over-quarter from $129000.0 in Q3 2025.
Supernus Pharmaceuticals (SUPN) Capital Expenditures (2011 - 2025) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 14 years of Capital Expenditures data on file, last reported at $427000.0 in Q4 2025.
- Capital Expenditures for Q4 2025 came in at $427000.0, up 100.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (up 25.75% YoY), and the FY2025 annual result was $1.3 million, up 84.55% from the prior year.
- Capital Expenditures improved to $427000.0 in Q4 2025 per SUPN's latest filing, from $129000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $549000.0 in Q1 2022 and troughed at -$274000.0 in Q2 2022.
- A 4-year average of $189125.0 and a median of $206500.0 in 2024 frame the typical range for Capital Expenditures.
- On a YoY basis, Capital Expenditures climbed as much as 691.67% in 2024 and fell as far as 59.75% in 2024.
- A 4-year view of Capital Expenditures shows it stood at -$168000.0 in 2022, then surged by 78.57% to -$36000.0 in 2023, then jumped by 691.67% to $213000.0 in 2024, then soared by 100.47% to $427000.0 in 2025.
- Business Quant data shows SUPN's Capital Expenditures at $427000.0 in Q4 2025, $129000.0 in Q3 2025, and $455000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 168.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 110.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 100.80 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 9.10 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 51.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 4.09 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 2.04 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 8.83 Mn |
| 10 | Supernus Pharmaceuticals | 2.57 Bn | 2.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 427,000.00 |
| Dec 31, 2025 | 427,000.00 |
| Sep 30, 2025 | 129,000.00 |
| Sep 30, 2025 | 129,000.00 |
| Jun 30, 2025 | 455,000.00 |
| Jun 30, 2025 | 455,000.00 |
| Mar 31, 2025 | 327,000.00 |
| Mar 31, 2025 | 327,000.00 |
| Dec 31, 2024 | 213,000.00 |
| Dec 31, 2024 | 213,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Dec 31, 2023 | -36,000.00 |
| Dec 31, 2023 | -36,000.00 |
| Sep 30, 2023 | 150,000.00 |
| Sep 30, 2023 | 150,000.00 |